TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in…
Article content Results from a prespecified analysis of the Phase 3 LUCIDITY trial show reduction in neurodegeneration biomarker (NfL) in AD for people receiving 16 mg/day of HMTM compared to controls HMTM is an oral drug with a strong…